Top Medical News
21 hours ago
Higher body fat content at baseline in patients with ankylosing spondylitis (AS) is likely to weaken response to treatment with tumour necrosis factor-α (TNF-α) blockers, measured by the Ankylosing Spondylitis Disease Activity Score containing C-reactive protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), suggests a recent study.
Etanercept therapy for a period of 5 years leads to small changes in serum lipid concentrations, which are inversely correlated with inflammatory markers, according to a recent study. Other cardiovascular disease (CVD) risk factors remain stable.
Audrey Abella, 6 days ago
The interleukin-6 receptor-alpha inhibitor tocilizumab alone or in combination with methotrexate demonstrated clinical benefit after 2 years of treatment in methotrexate-naïve patients with early rheumatoid arthritis (RA), according to the FUNCTION* trial.
14 Sep 2017
Compared with other types of spondyloarthritis (SpA), SpA associated with inflammatory bowel disease (IBD-SpA) has significantly less frequency of dactylitis, enthesitis and anterior uveitis (AU), a recent study has found.
13 Sep 2017
Oral contraceptives may cut the risk of developing rheumatoid arthritis (RA), especially anticitrullinated protein antibodies (ACPA)-positive RA, a study has found. Furthermore, long duration of OC use protects against the risk of both ACPA-positive and ACPA-negative RA.
11 Sep 2017
Calprotectin appears to be associated with clinical measures of disease activity and ultrasound inflammation in treatment-naïve patients with rheumatoid arthritis (RA), a study has found.
07 Sep 2017
The presence of rheumatoid factor (RF) rather than anticyclic citrullinated peptide antibodies (anti-CCP) may predict 10-year cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA), a recent study has found.
Special Reports
03 Apr 2017
At the International Osteoporosis Foundation Regionals – 6th Asia-Pacific Osteoporosis Meeting in Singapore, Professor Olivier Bruyère shared about the algorithm for the management of knee OA by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). MIMS Doctor also spoke to Professor Jean-Yves Reginster, president of ESCEO about this algorithm and the role of SYSADOAs in the control of pain and prevention of disease progression.
07 Mar 2017
At the 17th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.
18 Aug 2016
During the combined meeting of the 46th Malaysian Orthopaedic Association Annual General Meeting/Annual Scientific Meeting and the 10th ASEAN Arthroplasty Association Meeting, Dr Joseph Pergolizzi spoke on the importance of chronic pain control and appropriate strategies to achieve this. Highlights of his presentation are summarized below.
09 Oct 2015
Calcium and vitamin D play a major role in the prevention and treatment of osteoporosis. In this exclusive interview with MIMS Doctor, Dr Yeap Swan Sim talks about the importance of calcium and vitamin D in bone health, as well as the current status of these micronutrients in local postmenopausal women.
13 May 2015
Recently, MIMS Doctor sat down with Associate Professor Dr Sabarul Afian Mokhtar to get his perspectives on the use of monoclonal antibody for the treatment of postmenopausal osteoporosis (PO) and also important learning from the International Osteoporosis Foundation (IOF) Regionals 5th Asia-Pacific Osteoporosis Meeting. Highlights from the interview are presented here.
Naomi Adam, 01 Feb 2014

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, the underlying cause of which is not fully known. Recently, biologic disease-modifying anti-rheumatic drugs (DMARDs) have started to be considered for the treatment of SLE due to their improved tolerability profiles compared with conventional therapies. This report profiles belimumab, a novel biologic DMARD, which has been approved for use in the treatment of certain patients with SLE.

Conference Reports
11 Jul 2017
Slideshow: Highlights from the European League Against Rheumatism (EULAR) Annual Congress 2017
Jackey Suen, 07 Jul 2017

The experimental drug ABT-981 fails to show significant improvements in pain and joint symptoms compared with placebo in patients with hand osteoarthritis (OA), according to a phase IIa trial presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 held in Madrid, Spain. 

Elaine Tan, 29 Jun 2017

Tofacitinib, a first-in-class Janus kinase (JAK) inhibitor, shows promise as an oral treatment with quick onset of action and sustained efficacy in patients with psoriatic arthritis (PsA) who do not respond adequately to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). 

Dr. Joseph Delano Fule Robles, 27 Jun 2017

AMG-557, an inducible T-cell costimulator (ICOS) ligand inhibitor, showed efficacy and safety in a randomized multicentre trial that included patients with lupus arthritis from eight centres in the US, France, Malaysia and Germany. 

Christina Lau, 26 Jun 2017

Feelings of injustice and low socioeconomic status can have a significant impact on disease severity in patients with fibromyalgia, according to data from a large survey presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 held recently in Madrid, Spain.

Jackey Suen, 23 Jun 2017

The fully-human immunocytokine dekavil (also known as F8-IL10) has demonstrated signs of safety and efficacy in patients with active rheumatoid arthritis (RA) in a phase I study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017.

Dr. Joseph Delano Fule Robles, 23 Jun 2017

Vobarilizumab, a nanobody consisting of an anti-interleukin 6 (IL-6) receptor domain developed for the treatment of rheumatoid arthritis (RA), is shown to be safe and efficacious in RA patients with inadequate response to methotrexate in a study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 held recently in Madrid, Spain.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!